Relief Therapeutics Holding AG (RLFTF)

[C504]

Found three new trials coming:

https://clinicaltrials.gov/ct2/show/NCT04843761?term=Aviptadil&draw=2&rank=6

https://www.clinicaltrials.gov/ct2/show/NCT04844580?term=NCT04844580

https://advita-lifescience.com/newsroom/

Translation of the AdVita PR:

14 April 2021
AdVita Lifescience AG is sponsoring a Phase II study in Switzerland entitled:
"Inhaled Aviptadil for the prevention of COVID-19 related Acute Respiratory Distress Syndrome (ARDS) - a randomized, double-blind, placebo controlled, multi center trial."

Swissmedic and the relevant ethics committee have approved the protocol for implementation in several Swiss test centres.
The study medication was produced by a Swiss company and the first patients can be included.

The aim of the study is to determine whether COVID-19 patients at high risk of developing ARDS recover more quickly if they are treated with inhaled aviptadil in addition to standard care.

Dr Urs Breitenstein is a founding Partner of Hoffman & Partner. One of the leading M&A and Corporate Finance experts in Switzerland, he advises companies from sectors including life sciences, finance, consumer goods and manufacturing on the financing, acquisition or disposal of companies, and on valuation issues (including assessments in line with IFRS and other accounting standards). Alongside his work for Hoffmann & Partners’ clients, Dr Breitenstein is regularly consulted as an independent valuation expert in disputes and lawsuits.

Before co-founding Hoffmann & Partner, Dr Breitenstein worked for Basler Kantonalbank, PricewaterhouseCoopers and, most recently, for Deloitte in Zurich, where he was a partner and team leader. He developed the valuation and business modelling team in Switzerland and was simultaneously responsible for the mergers and acquisitions department. Dr Breitenstein has also worked on several international projects, providing him with outstanding expertise in complex cross-border assessments and corporate transactions.

Dr Urs Breitenstein studied at the graduate school of the Swiss National Bank in Gerzensee and holds a doctorate in economics (Dr. rer. pol.) from the University of Basel.


25 March 2021
AdVita Lifescience GmbH establishes a subsidiary in Basel,
AdVita Lifescience AG.

AdVita Lifescience AG will coordinate the activities in Switzerland, e.B. a study at COVID-19.

20 January 2021

Relief Therapeutics Holding AG and AdVita Lifescience GmbH sign a binding memorandum of understanding for the acquisition of all shares of AdVita Lifescience GmbH by Relief Therapeutics Holding AG to extend the development program of the inhaled Aviptadil formulation.